Halting resurgent prostate cancers before they spread
Q&A: Prostate cancer expert Julie Graff, M.D., explains how a new treatment option fills a void for men with resurgent tumors. When prostate cancer isn't cured by surgery or radiation, the...
Cracking the code of advanced prostate cancer
Figure: age-adjusted cancer death rates per 100,000 U.S. men, by tumor site (American Cancer Society)For men in the U.S., prostate cancer is the second-leading cause of cancer death. Not all prostate...
A new line of attack on deadly prostate cancers
Researchers have uncovered a potential drug target for stopping castration-resistant prostate tumors – the second leading cause of cancer death in the U.S. For decades, drug development for...
Exercise as medicine for cancer: Q&A with Kerri Winters-Stone
Cancer patients don’t need to avoid physical exertion, including exercise – contrary to once widely held belief. Exercise is not only safe during and after cancer treatment, studies have found...
An elaborate clinical trial aims a multitude of targeted therapies at one formidable cancer
A $10 million gift from The Harry T. Mangurian Jr. Foundation will help The Leukemia & Lymphoma Society expand the Beat AML Master Trial underway at the OHSU Knight Cancer Institute and other...
Study reveals factors outside of tumors that steer breast cancer aggressiveness
Cancer researchers have identified key factors in the surroundings of tumor cells that it may be possible to target to improve outcomes for patients with HER2-positive breast cancer. Co-principal...
Making sense of colorectal cancer screening choices
Colorectal cancer is the third most common cause of cancer death among men and women in the U.S. But there is shockingly large regional variation in mortality, in part because of sharp differences...
Taking stock of the evidence for ‘off-label’ use of cancer drugs
Doctors often expand the use of cancer drugs to situations beyond those explicitly approved by the Food and Drug Administration. And health plans will pay for those uses as long as they are supported...
Cancer clinical research scholars move discoveries from lab to patients
Five oncologists at Oregon Health & Science University in Portland will receive a $25,000 salary supplement for one year, allowing them to reserve time to pursue promising research...
What magnitude of benefit is meaningful to cancer patients?
Oncologists often use the phrase "clinically meaningful benefit" to describe the effect of an experimental treatment. But is the benefit meaningful for patients? A new paper suggests that benefit...
Cancer translated’s top blog posts of 2017
From basic science to survivorship and patient advocacy, the OHSU Knight Cancer Institute’s 'Cancer translated' blog explores new ideas and debates in cancer medicine. We sorted a year’s worth...